Angptl3 Inhibitors
Angiopoietin-like 3 (ANGPTL3) is a critical regulator of lipid metabolism, with roles spanning the modulation of triglyceride levels, cholesterol distribution, and lipoprotein processing. Its activity is integral to the management of lipid fluxes within the bloodstream, influencing the activity of enzymes such as lipoprotein lipase (LPL) and endothelial lipase, thereby controlling the clearance and distribution of triglycerides and cholesterol. ANGPTL3's expression in the liver and secretion into the bloodstream position it as a central molecular player in systemic lipid regulation. The inhibition of ANGPTL3, therefore, presents a strategic target for modulating lipid metabolism, with implications for managing dyslipidemias and related metabolic disorders.
The general mechanism of inhibiting ANGPTL3, given the constraints against using biological agents, leans towards indirect approaches through the modulation of lipid metabolism pathways and related signaling cascades. Compounds that influence cholesterol synthesis, fatty acid oxidation, and lipid absorption can alter the metabolic landscape in which ANGPTL3 operates, potentially reducing its expression or blunting its activity. This can be achieved through the activation of PPARα and PPARγ, inhibition of cholesterol absorption or synthesis, and modulation of triglyceride levels in the bloodstream. Such indirect inhibitors operate within the broader context of lipid metabolism, affecting the availability of substrates or the expression of co-regulatory proteins that in turn influence ANGPTL3's role in lipid homeostasis. Through these multifaceted interactions, the modulation of lipid metabolism offers a viable strategy for the indirect inhibition of ANGPTL3, targeting its contribution to lipid regulation without directly interacting with the protein itself.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate activates peroxisome proliferator-activated receptor alpha (PPARα), enhancing the oxidation of fatty acids and reducing triglyceride levels. This action can indirectly decrease ANGPTL3 expression, as ANGPTL3 is downregulated by activated PPARα signaling. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Atorvastatin inhibits HMG-CoA reductase, leading to lowered cholesterol synthesis. Reduced intracellular cholesterol can modulate lipid metabolism pathways indirectly affecting ANGPTL3 levels by altering lipid homeostasis. | ||||||
Ezetimibe | 163222-33-1 | sc-205690 sc-205690A | 25 mg 100 mg | $96.00 $241.00 | 12 | |
Ezetimibe inhibits the Niemann-Pick C1-like 1 protein, reducing cholesterol absorption in the intestine. This alteration in cholesterol and lipid metabolism may indirectly influence ANGPTL3 activity by affecting systemic lipid levels. | ||||||
Nicotinic Acid | 59-67-6 | sc-205768 sc-205768A | 250 g 500 g | $62.00 $124.00 | 1 | |
Niacin binds to the GPR109A receptor, influencing lipid metabolism through antilipolytic effects in adipose tissue and reducing serum triglycerides. These changes can indirectly modulate ANGPTL3 activity by altering its regulatory environment. | ||||||
Gemfibrozil | 25812-30-0 | sc-204764 sc-204764A | 5 g 25 g | $66.00 $267.00 | 2 | |
Gemfibrozil acts on PPARα to reduce triglyceride levels, similar to fenofibrate. It may indirectly influence ANGPTL3 by modifying lipid metabolism and reducing the availability of triglycerides, which ANGPTL3 regulates. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $145.00 | 8 | |
Rosuvastatin, another HMG-CoA reductase inhibitor, lowers cholesterol synthesis and may indirectly affect ANGPTL3 by impacting lipid metabolism pathways and cholesterol homeostasis. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone activates PPARγ, influencing glucose and lipid metabolism. This could indirectly affect ANGPTL3 by altering the metabolic context in which ANGPTL3 functions, particularly in lipid processing and glucose regulation. | ||||||
Berberine | 2086-83-1 | sc-507337 | 250 mg | $92.00 | 1 | |
Berberine has been shown to influence lipid metabolism through various mechanisms, including activation of AMP-activated protein kinase (AMPK). This can indirectly affect ANGPTL3 activity by altering the metabolic pathways that regulate lipid homeostasis and cholesterol levels. | ||||||